Altimmune ALT announced that the FDA has granted Breakthrough Therapy Designation to its lead pipeline candidate, pemvidutide ...

Rezdiffra FDA approval fuels sales; expansion to F4 MASH cirrhosis with 2027 trial data. Read more about MDGL stock here.

A silent health crisis may be developing inside your body without any obvious warning signs. Metabolic dysfunction-associated steatohepatitis (MASH) represents a serious form of fatty liver disease ...

Breakthrough Therapy Designation is intended to expedite the development and review of medicines that are intended to treat a serious or life-threatening condition and have shown preliminary clinical ...

Dan Marino is opening up about his health — and offering reassurance to fans in the process. The NFL Hall of Famer, 64, gives ...

Altimmune said its therapy, pemvidutide, demonstrated statistically significant resolution of MASH without worsening of fibrosis in a recent Phase 2b trial. The trial results also showed early and ...

The key opportunities in the MASH treatment market include focusing on the drug segment, especially FGF21-based therapies, ...

Altimmune Inc. (NASDAQ: ALT) on Friday shared topline results from the IMPACT Phase 2b trial of pemvidutide. Patients had metabolic dysfunction-associated steatohepatitis (MASH) at 48 weeks. MASH is a ...

A Boehringer Ingelheim drug in development for weight loss now has data from a separate mid-stage clinical trial showing dramatic reductions across several measures of a fatty liver disease whose ...

Imagine sitting in a doctor’s office and being told you have “non-alcoholic” liver disease. Before the doctor even finishes explaining what that means, your brain is already doing gymnastics trying to ...

MASH patients exhibit a higher spleen-to-liver stiffness ratio than ALD patients, indicating a presinusoidal component in portal hypertension. The study found that MASH patients have larger spleen ...

The MarketWatch News Department was not involved in the creation of this content. -- Secondary analyses of the ESSENCE trial were presented at the American Association for the Study of Liver Diseases ...